Hot Investor Mandate 4: USA-Based Evergreen Fund Invests in Therapeutics, Medical Devices, Diagnostics

Featured Posts

• In Partnership with KOTRA: Uncovering the Korean Biotech Start-Up Scene at RESI Boston

  By Claire Jeong, Research Analyst, LSN Even with the RESI Boston conference less than 3 weeks away, the upcoming conference continues to attract an international crowd of early-stage companies and investors. In last week’s newsletter, we discussed how over 1/3 of the registered attendees are coming from firms based outside of the USA. For this particular […]

• Finding Investment Opportunities At RESI: An Interview with Andy Li (Biosense Global)

  An interview with Andy Li, CEO & President, Biosense Global – By Jessica Yang, Investor Research Analyst, LSN Earlier this week, I had the pleasure of speaking with Dr. Andy Li, the founding partner of Biosense Global LLC. Andy has attended nearly every RESI event in the last 2 years. RESI is a partnering event […]

• Big Pharmas Explain Partnering Strategy At RESI On June 4th

  By Lucy Parkinson, VP of Investor Research, LSN In recent years, big pharma companies have begun looking outwards for innovative new therapeutics to add to their pipelines.  RESI has become a venue for these major players to make connections with early stage biotech companies, and RESI includes a panel on Big Pharma to provide entrepreneurs […]

• Hot Investor Mandate 1: Firm Partnered with a Family Office Seeking to Provide Seed Capital to USA-Based Therapeutics Opportunities

  A Chicago-based life sciences investment fund is focused on accelerating the growth of early-stage biotechnology and pharmaceutical companies. Partnered with a family investment office, the firm seeks to make 10 seed round investments within the next year. The firm will invest in companies based in the U.S. The firm is seeking investments in biotech/therapeutics companies […]

• Hot Investor Mandate 2: Company Acquired by Chinese Pharma Seeks Early to Mid-Stage Therapeutics Partnering Opportunities, Capable of Investing Up to $100M

  A spin-out pharmaceutical company recently acquired by a Chinese pharmaceutical company is seeking early to mid-stage technology for equity, in-licensing, and acquisition opportunities, and typically invests $10M to $100M per project depending on the opportunity. In the past several years, the company also acquired two USA companies at $200-300M range. The company is seeking opportunities […]